The LOI of IGF-II in normal prostate tissue was found to increase with age in mouse and humans and this was more extensive in men with prostate cancer and, in mice, the age-related effect was associated with a decrease in CTCF levels and its binding to the IGF-II/H19 ICR [185]. This evidence concerns the gene IGF2 and prostate carcinoma.